Rilzabrutinib Medical Launch Lead

Rilzabrutinib Medical Launch Lead

The role reports to the Global Head of Rare Launch and Pipeline Portfolio within the Global Medical Rare Disease Organization.

Sanofi Rare Diseases has built trust and a solid partnership with the rare community through more than 30 years of leadership, innovation, and respect for the needs of patients suffering from Rare Genetic Disorders. As the Company continues to respond to these needs and aims to address new unmet medical needs, such as Rare Blood Disorders, the Medical Launch team is committed to excellence in our efforts to bring to the market a new best-in-class treatment option for patients suffering from ITP.

This position leads medical strategy within the Global Development Team, works closely with the GPH, and serves as Medical Lead on this launch. Among other responsibilities, this person will be expected to drive the Medical activities pre-launch and interface with key internal and external stakeholders across multiple teams to foster the development and implementation of strategic medical plans during waive-1 of regulatory submissions and approvals. This highly exposed position offers a relevant opportunity to gain expertise in several areas and continuous mentorship.

We are an innovative global healthcare company, committed to transforming the lives of people with immune challenges, rare diseases and blood disorders, cancers, and neurological disorders. From R&D to sales, our talented teams work together, revolutionizing treatment, continually improving products, understanding unmet needs, and connecting communities. We chase the miracles of science every single day, pursuing progress to make a real impact on millions of patients around the world.

Main Responsibilities

• Accountable for developing and implementing the Global Brand Medical strategy and action plan for Rilzabrutinib's implementation of the medical strategy globally.
• Serve as Medical representative, providing appropriate cross-functional expertise and ensuring execution of critical medical strategies within the Rilzabrutinib Global Development Team.
• Lead strategy behind the Evidence Generation Plan to support product development, working alongside the Medical Evidence Generation team, Global Product Team, and Rilzabrutinib Medical Director
• Drive the development and Global execution of the Managed Access Program for Rilzabrutinib in ITP and wAIHA.
• Define the Global strategy for Clinical Insights, KOL mapping, and Message dissemination.
• Provide Medical expertise for the design and execution of potential new clinical studies, considering clinically relevant, patient-centric outcomes.
• Lead Medical responsibilities within the Global Labelling process across Rilzabrutinib indications.
• Contribute to planning, resourcing, and budget decisions for implementing the Global Medical Roadmap for the launch of Rilzabrutinib across indications.

About You

Why Choose Us?

Sanofi Inc. and its U.S. affiliates are Equal Opportunity and Affirmative Action employers committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status; domestic violence victim status; atypical cellular or blood trait; genetic information (including the refusal to submit to genetic testing) or any other characteristic protected by law.